Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Aug 13;10(1):13736.
doi: 10.1038/s41598-020-70833-1.

Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema

Affiliations
Observational Study

Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema

Moon Young Choi et al. Sci Rep. .

Abstract

We designed a retrospective observational study to identify factors associated with ocular hypertension [OHTN, defined as intraocular pressure (IOP) > 25 mmHg] after intravitreal dexamethasone (IVD) implantation in diabetic macular edema (DME) patients. We measured IOP monthly after placement of an IVD implant, and identified the trend of IOP, incidence of OHTN, and its associated systemic or ocular factors. On average, IOP was highest at 2 months after IVD implantation. Of 84 DME patients who received an IVD implant, 3 (3.57%) presented with an IOP ≥ 25 mmHg at 1 month after implantation, 6 (7.14%) at 2 months, and 2 (2.38%) at 3 months. Compared with the non-OHTN group, the OHTN group had significantly shorter axial lengths and were younger. Logistic regression analysis revealed that axial length < 23.00 mm and age < 57 years were associated with OHTN occurrence. Patients whose IOP was elevated > 30% or ≥ 20 mmHg at 1 month post-implantation, subsequently developed OHTN with statistical significance. In conclusion, shorter axial length and younger age were associated with OHTN occurrence after IVD implantation. Additionally, identifying levels or trends in IOP at 1 month after the IVD procedure may be helpful in predicting subsequent OHTN occurrence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Changes in average intraocular pressure (IOP) after the intravitreal dexamethasone implant procedure. The IOP was measured at baseline, and at 1, 2, and 3 months after the procedure. The highest average IOP occurred at 2 months after the procedure but had decreased by the 3-month check-up.

References

    1. Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: A worldwide perspective. Surv. Ophthalmol. 2012;57:347–370. doi: 10.1016/j.survophthal.2012.01.004. - DOI - PubMed
    1. VanderBeek BL, Shah N, Parikh PC, Ma L. Trends in the care of diabetic macular edema: Analysis of a national cohort. PLoS ONE. 2016;11:e0149450. doi: 10.1371/journal.pone.0149450. - DOI - PMC - PubMed
    1. Das A, McGuire PG, Rangasamy S. Diabetic macular edema: Pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122:1375–1394. doi: 10.1016/j.ophtha.2015.03.024. - DOI - PubMed
    1. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011;30:343–358. doi: 10.1016/j.preteyeres.2011.05.002. - DOI - PMC - PubMed
    1. Wells JA, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med. 2015;372:1193–1203. doi: 10.1056/NEJMoa1414264. - DOI - PMC - PubMed

Publication types

MeSH terms